Alex Chompff

Skip to content The CRC Digest ◇ RESEARCH Researchers question whether lymph node removal may impair immunotherapy response — Colorectal Disease A hypothesis-generating review examines whether routine lymphadenectomy (removal of ≥12 lymph nodes, a well-recognized quality indicator in colorectal cancer surgery) may theoretically impair systemic immune surveillance and immune checkpoint inhibitor (ICI)

Skip to content The CRC Digest ◇ RESEARCH CT radiomics identifies imaging biomarkers in RAS-mutant metastatic colorectal cancer — European Journal of Radiology Researchers established a co-clinical computed tomography (CT) radiomics pipeline for identifying candidate imaging biomarkers in RAS-mutant metastatic colorectal cancer. Orthotopic KRAS-mutant xenograft models (LOVO-Luc2 and SW480-Luc2, N=52 each)

Skip to content The CRC Digest ◇ RESEARCH Irisin enhances 5-fluorouracil effectiveness in colon cancer cells — International Journal of Applied and Basic Medical Research Human HT-29 CRC cells were treated for 12 hours with irisin (2, 20, and 200 ng/mL) alone or combined with 5-FU (50 μM). Cell cycle progression

Skip to content The CRC Digest ◇ RESEARCH Scientists identify metabolic pathway driving cetuximab resistance — Cell Death & Disease Researchers discovered that glutamate dehydrogenase 1 (GDH1) accumulation drives cetuximab resistance in metastatic colorectal cancer. When cetuximab blocks EGFR, it prevents phosphorylation of GDH1, leading to its accumulation and increased production of

Skip to content The CRC Digest ◆ TRIAL DATA Alpelisib plus capecitabine shows modest activity in PIK3CA-mutant metastatic colorectal cancer — Scientific Reports A phase 2 study tested alpelisib (a PI3K inhibitor) combined with capecitabine in 26 patients with PIK3CA-mutant metastatic colorectal cancer who had progressed after standard chemotherapy. The trial was

Skip to content The CRC Digest ▸ TREATMENT Re-challenging BRAF V600E tumors with encorafenib, cetuximab, and nivolumab shows success — Clinical Colorectal Cancer A case report from the AGMT mCRC Registry documented successful re-challenge with encorafenib and cetuximab combined with nivolumab in a patient with BRAF V600E mutated, mismatch-repair-proficient (pMMR) metastatic colorectal

Skip to content The CRC Digest ▪ SCREENING Blood test detects colorectal cancer recurrence earlier than imaging in stage III patients — Cancer Diagnosis & Prognosis A retrospective case series of four patients with stage III colorectal cancer demonstrated the clinical utility of the Signatera assay, a personalized circulating tumor DNA (ctDNA)

Skip to content The CRC Digest ◆ TRIAL DATA Adding celecoxib to immunotherapy increases complete response in MSI-H colorectal cancer — Lancet Oncology A phase 2 trial tested whether adding celecoxib (a COX-2 inhibitor) to the immunotherapy drug toripalimab would improve outcomes in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H)